ReviewFrontiers in bioengineering and biotechnology2026
Antioxidant biomaterials in intervertebral disc regeneration: current status and future clinical translation.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intervertebral disc degeneration (IVDD) is a leading cause of chronic back pain and long-term disability, imposing a substantial burden on healthcare systems worldwide. At the core of this degenerative process lies oxidative stress, a pathological condition driven by excessive accumulation of reactive oxygen species (ROS). This redox imbalance initiates a destructive cascade within the intervertebral disc, resulting in injury, premature senescence, and death of nucleus pulposus cells. The loss of these critical cells subsequently provokes inflammatory responses and degradation of the extracellular matrix, ultimately compromising the structural integrity of the disc. Although conventional clinical interventions effectively alleviate symptoms, they typically fail to target the underlying biological mechanisms or halt disease progression. This unmet therapeutic need has spurred growing interest in antioxidant materials, which offer a more proactive approach by directly neutralizing ROS and restoring redox homeostasis. Beyond mere ROS scavenging, these materials also mitigate inflammation and foster a microenvironment supportive of tissue regeneration. Current research efforts are increasingly focused on the rational design of such antioxidant systems, particularly their integration with advanced cell-based therapies to enhance regenerative outcomes. A detailed assessment of how these materials modulate specific pathological pathways is essential to clarify their practical utility and inherent limitations. Translating promising laboratory results into clinical practice remains a major challenge, necessitating rigorous evaluation of their performance in complex biological settings. Refining these antioxidant strategies may ultimately pave the way for a paradigm shift, from symptomatic relief to genuine functional restoration in patients with IVDD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.